2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Immunoglobulin Light-chain Amyloidosis
2
Paraproteinemias
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Amyloid Neuropathies, Familial
1
Interventions
Specimen Handling
454
Magnetic Resonance Spectroscopy
347
pembrolizumab
289
Biopsy
244
Carboplatin
230
Cisplatin
194
Cyclophosphamide
186
Paclitaxel
164
Nivolumab
154
Gemcitabine
151
Radiotherapy
125
Bevacizumab
124
Dexamethasone
113
fludarabine
100
Pemetrexed
99
Fluorouracil
94
Doxorubicin
92
durvalumab
91
Radiation
91
Docetaxel
91
venetoclax
89
Rituximab
88
Oxaliplatin
88
atezolizumab
87
Leucovorin
79
Capecitabine
76
Prednisone
75
Lenalidomide
70
Etoposide
69
X-Rays
66
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
30 days
×
Clear all
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled